Further Weakness as Intellia Therapeutics (NASDAQ:NTLA) Drops 23% This Week, Taking Three-year Losses to 88%
Further Weakness as Intellia Therapeutics (NASDAQ:NTLA) Drops 23% This Week, Taking Three-year Losses to 88%
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of Intellia Therapeutics, Inc. (NASDAQ:NTLA) investors who have held the stock for three years as it declined a whopping 88%. That'd be enough to cause even the strongest minds some disquiet. And the ride hasn't got any smoother in recent times over the last year, with the price 33% lower in that time. The falls have accelerated recently, with the share price down 39% in the last three months. While a drop like that is definitely a body blow, money isn't as important as health and happiness.
地球上的每位投資者有時都會做出錯誤的決定。但你要避開像瘟疫一樣的真正巨大損失。所以請花點時間考慮一下Intellia Therapeutics, Inc. (NASDAQ:NTLA)的不幸投資者們,他們持有這隻股票已經三年了,股價已經暴跌了88%。即使是最堅強的人,也會因此感到不安。而最近一年裏,股價下跌了33%,這趟車並沒有變得更順暢。最近股價的下跌有所加速,過去三個月股價下跌了39%。雖然這樣的暴跌確實是個重擊,但金錢並不像健康和幸福那麼重要。
If the past week is anything to go by, investor sentiment for Intellia Therapeutics isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
如果過去一週可以作爲參考,那麼對Intellia Therapeutics的投資者情緒並不樂觀,因此讓我們看看基本面和股價之間是否存在不匹配。
Intellia Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.
Intellia Therapeutics在過去十二個月中沒有盈利,我們不太可能看到其股價和每股收益(EPS)之間存在強烈相關性。可以說,營業收入是我們的下一個最佳選擇。當一家公司沒有盈利時,我們通常希望看到良好的營業收入增長。一些公司願意推遲盈利以加快營收增長,但在這種情況下,人們希望看到良好的營收增長來彌補盈利缺乏的問題。
In the last three years, Intellia Therapeutics saw its revenue grow by 11% per year, compound. That's a fairly respectable growth rate. So it seems unlikely the 23% share price drop (each year) is entirely about the revenue. It could be that the losses were much larger than expected. This is exactly why investors need to diversify - even when a loss making company grows revenue, it can fail to deliver for shareholders.
在過去的三年中,Intellia Therapeutics的營業收入以每年11%的複合增長率增長。這是一個相當可觀的增長率。因此,23%的股價下跌(每年)看起來不太可能完全是關於營業收入的問題。可能虧損遠遠大於預期。這正是投資者需要分散投資的原因 - 即使是一家虧損的公司增長了營收,也可能無法爲股東帶來回報。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。
Intellia Therapeutics is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. You can see what analysts are predicting for Intellia Therapeutics in this interactive graph of future profit estimates.
intellia therapeutics爲投資者所熟知,許多聰明的分析師都試圖預測未來的利潤水平。您可以查看分析師對intellia therapeutics的未來利潤預估交互式圖形。
A Different Perspective
不同的觀點
While the broader market gained around 41% in the last year, Intellia Therapeutics shareholders lost 33%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 5% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Intellia Therapeutics better, we need to consider many other factors. For instance, we've identified 2 warning signs for Intellia Therapeutics that you should be aware of.
在過去一年中,更廣泛的市場漲幅約爲41%,而intellia therapeutics的股東則損失了33%。即使是好股票的股價有時也會下跌,但在變得過於感興趣之前,我們希望看到企業基本指標的改善。從好的一面來看,長期股東已經賺錢,過去半個十年的年均增長率爲5%。最近的拋售可能是一個機會,因此值得檢查基本數據是否顯示出長期增長趨勢的跡象。長期跟蹤股價表現總是有趣的。但要更好地了解intellia therapeutics,我們需要考慮許多其他因素。例如,我們已經確定了intellia therapeutics存在2個警告信號,您應該注意。
But note: Intellia Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:intellia therapeutics可能不是最佳買入股票。因此,看看這份包含過去盈利增長(以及未來增長預測)的有趣公司免費名單吧。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。